ArticleSurgery today2026
The prognostic value of serum lactate dehydrogenase levels in patients with carcinoembryonic antigen (CEA)- and carbohydrate antigen 19-9 (CA19-9)-negative colorectal cancer.
Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Upfront Thermal Ablation versus Neoadjuvant Chemotherapy Followed by Ablation for Oligometastatic Colorectal Liver Metastases: A Propensity Score Matching Analysis.Cardiovascular and interventional radiology · 2026Article
- Real-world short-term outcomes after distal pancreatectomy with en bloc celiac axis resection using the National clinical database of Japan.Surgery today · 2026Article
- A comparison of laparoscopic and robotic distal pancreatectomy with spleen and Splenic vessels preservation: an intention-based evaluation in a single-center retrospective study.Surgery today · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeLactate dehydrogenase (LDH) is an enzyme involved in the cellular energy metabolism of cancer cells. We conducted this study to evaluate serum LDH as a prognostic marker for predicting the outcomes of colorectal cancer (CRC) patients with negative carcinoembryonic antigen (CEA) and carbohydrate antigen 19 - 9 (CA19-9) levels.
methodsThe subjects of this retrospective study were 369 patients with stage II/III CRC and negative preoperative CEA and CA19-9 levels. Serum LDH levels were measured within 4 weeks before surgery and the association between serum LDH levels and survival outcomes was investigated.
resultsFifty-five (15%) of the 369 patients had a high LDH of ≥ 212 U/L (high LDH group). Multivariate analysis identified that N stages 1‒3 (P = 0.019), serum LDH levels ≥ 212 U/L (P = 0.038), and a modified Glasgow Prognostic Score of 2 (P = 0.031) were independent predictors of disease-free survival (DFS). American Society of Anesthesiologists physical status ≥ 3 (P = 0.019), N stages 1‒3 (P = 0.009), and serum LDH levels ≥ 212 U/L (P < 0.001) were also independent predictors of overall survival (OS).
conclusionThe serum LDH level is a valuable prognostic marker for predicting the outcomes of CRC patients, even those with negative CEA and CA19-9 levels.
Indexed as
Identifiers
41384977What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.